School of Health Systems and Public Health, Epidemiology & Biostatistics, University of Pretoria, 5-10 H.W. Snyman Building, Pretoria, South Africa.
, 47 Newstead Road, Harare, Marlborough, Zimbabwe.
Syst Rev. 2018 Jan 25;7(1):22. doi: 10.1186/s13643-018-0686-9.
Cervical cancer has become the most common cancer affecting women in Africa. Significantly, 85% of these annual deaths occur in the developing world, with the majority being middle-aged women. Research has shown that in sub-Saharan Africa, cervical cancer trends are on the rise in the past two decades because of HIV and this has resulted in an increase in cervical cancer cases among young women. However, little or no information exists that has shown that any of the available treatment methods are more effective than others when it comes to treating cervical cancer in HIV-seropositive women. The aim of this protocol is to offer a plan on how to systematically review cervical cancer treatment methods available for HIV-seropositive women in developing countries.
METHODS/DESIGN: The Preferred Reporting Items for Systematic Reviews and Meta-Analyses Protocols (PRISMA-P) statement was used to develop the protocol for the systematic review which will be reported in accordance with the PRISMA guidelines. A number of databases, Embase, MEDLINE, PubMed, CINAHL and Cochrane Library, will be searched for relevant studies, and citation and reference list tracking will be used to search for additional studies. Prospective and retrospective cohort studies, case-control, randomised controlled trials and cross-sectional studies that were carried out in and for the developing world will be eligible for inclusion. Peer-reviewed studies and grey literature examining cervical cancer treatment modalities in HIV-seropositive women will be included. Descriptive statistics and tables will be used to summarise results, and meta-analysis will be used where appropriate.
The review findings will provide the current picture of the existing treatment methods being used to treat cervical cancer in HIV-seropositive women in developing countries. The findings might be used for the establishment of evidence-based guidelines for treatment of cervical cancer in seropositive women as well as prompt policy-makers and governments to decide and support future research in a way to find a lasting solution.
PROSPERO CRD42017054676 https://www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=54676.
宫颈癌已成为非洲女性最常见的癌症。值得注意的是，这些每年的死亡人数中有 85%发生在发展中国家，其中大多数是中年妇女。研究表明，在撒哈拉以南非洲，由于艾滋病毒的影响，宫颈癌在过去二十年中的发病率呈上升趋势，这导致年轻女性中的宫颈癌病例有所增加。然而，几乎没有或没有信息表明，在治疗艾滋病毒血清阳性妇女的宫颈癌方面，现有的任何治疗方法都比其他方法更有效。本方案旨在提供一种针对发展中国家艾滋病毒血清阳性妇女的宫颈癌治疗方法的系统评价计划。
方法/设计：采用系统评价和荟萃分析首选报告项目（PRISMA-P）声明制定系统评价方案，该方案将按照 PRISMA 指南进行报告。将检索 Embase、MEDLINE、PubMed、CINAHL 和 Cochrane 图书馆等多个数据库，以查找相关研究，并使用引文和参考文献跟踪来查找其他研究。符合条件的研究包括在发展中国家进行和针对发展中国家的前瞻性和回顾性队列研究、病例对照研究、随机对照试验和横断面研究。将纳入评估艾滋病毒血清阳性妇女宫颈癌治疗方法的同行评审研究和灰色文献。将使用描述性统计和表格来总结结果，并在适当的情况下进行荟萃分析。
该综述的结果将提供目前在发展中国家艾滋病毒血清阳性妇女中用于治疗宫颈癌的现有治疗方法的情况。该结果可用于为血清阳性妇女的宫颈癌治疗建立循证指南，并促使决策者和政府决定并支持未来的研究，以找到持久的解决方案。
PROSPERO CRD42017054676 https://www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=54676。
